



# Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures

Mallorie Boron<sup>1</sup> Tiffany Hauzer-Martin<sup>1</sup> Joseph Keil<sup>1</sup> Xue-Long Sun<sup>1</sup> 

<sup>1</sup>Department of Chemistry and Chemical and Biomedical Engineering and Center for Gene Regulation in Health and Disease (GRHD), Cleveland State University, Cleveland, Ohio, United States

TH Open 2022;6:e194–e212.

**Address for correspondence** Xue-Long Sun, PhD, FAHA, Department of Chemistry, Chemical and Biomedical Engineering and Center for Gene Regulation in Health and Disease (GRHD), Cleveland State University, Cleveland, OH 44115, United States (e-mail: x.sun55@csuohio.edu).

## Abstract

Thrombomodulin (TM) is a type-I transmembrane protein that is mainly expressed on endothelial cells and plays important roles in many biological processes. Circulating TM of different forms are also present in biofluids, such as blood and urine. Soluble TM (sTM), comprised of several domains of TM, is the major circulating TM which is generated by either enzymatic or chemical cleavage of the intact protein under different conditions. Under normal conditions, sTM is present in low concentrations (<10 ng/mL) in the blood but is elevated in several pathological conditions associated with endothelial dysfunction such as cardiovascular, inflammatory, infection, and metabolic diseases. Therefore, sTM level has been examined for monitoring disease development, such as disseminated intravascular coagulation (DIC), sepsis and multiple organ dysfunction syndrome in patients with novel coronavirus disease 2019 (COVID-19) recently. In addition, microvesicles (MVs) that contain membrane TM (MV-TM) have been found to be released from activated cells which also contribute to levels of circulating TM in certain diseases. Several release mechanisms of sTM and MV-TM have been reported, including enzymatic, chemical, and TM mutation mechanisms. Measurements of sTM and MV-TM have been developed and explored as biomarkers in many diseases. In this review, we summarize all these advances in three categories as follows: (1) release mechanisms of circulating TM, (2) methods for measuring circulating TM in biological samples, and (3) correlation of circulating TM with diseases. Altogether, it provides a whole picture of recent advances on circulating TM in health and disease.

## Keywords

- ▶ circulating thrombomodulin
- ▶ COVID-19
- ▶ endothelial cell
- ▶ microvesicle
- ▶ sepsis
- ▶ soluble thrombomodulin
- ▶ thrombomodulin
- ▶ vascular damage

## Introduction

### Thrombomodulin in General

Thrombomodulin (TM) is a type-I transmembrane glycoprotein that was first discovered by Esmon and Owen in 1981 on endothelial cells as a cofactor for thrombin-catalyzed activation of protein C.<sup>1</sup> This protein is encoded by an intronless gene (*THBD*) located on the chromosome 20p12-cen.<sup>2</sup> Since


its original identification, TM has also been found on a large variety of cells including macrophages, monocytes, platelets, neutrophils, and mesothelial cells.<sup>3–5</sup> Endothelial TM is made up of 557 amino acids with a molecular weight of approximately 74 kDa.<sup>6</sup> There are five total domains that make up the total structure of mature TM (▶**Fig. 1**). Starting from the *N*-terminus, these domains are the lectin-like

received  
October 29, 2021  
accepted  
March 11, 2022

DOI <https://doi.org/10.1055/a-1801-2055>.  
ISSN 2512-9465.

© 2022. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (<https://creativecommons.org/licenses/by/4.0/>)  
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany



**Fig. 1** Schematic presentation of structural domains of membrane thrombomodulin (TM) (A) and TM mutations (B), its release mechanisms of predicted sTMs with corresponding domains (C), and microvesicle-TM (C). CS, chondroitin sulfate; CTLD, C-type lectin-like domain; EGF, epidermal growth factor; RHBDL2, the intramembrane protease rhomboid-like-2; Ser, serine; sTM, soluble thrombomodulin; Thr, threonine.

domain (TMD1), epidermal growth factor (EGF)-like domain (TMD2), serine/threonine-rich domain (TMD3), transmembrane domain (TMD4), and a cytosolic tail (TMD5; **Fig. 1A**).<sup>6</sup> TM has multiple biological functions which are attributed to its different domains.<sup>7</sup> The lectin-like domain of TM is similar in structure to C-type lectins but lacks a calcium-binding site (named as C-type lectin domain [CTLD]). This domain is involved in inflammation, tumor growth, and cell adhesion. It exerts anti-inflammation actions by binding proinflammatory stimuli before they can reach their target. These include lipopolysaccharide (LPS) and high-mobility group box 1 protein.<sup>8,9</sup> For its role in cell adhesion, the lectin-like domain can bind to fibronectin of the extracellular matrix.<sup>10</sup> The TMD2 domain of TM contains six EGF-like repeats and is the site for TM's anticoagulation and fibrinolysis functions. These functions are allowed by TM's ability to activate protein C for anticoagulation, anti-inflammation, and thrombin activatable fibrinolytic inhibitor (TAFI) activation for fibrinolysis.<sup>11</sup> Both of these processes require thrombin, which requires EGF56 for binding.<sup>12,13</sup> It has been elucidated that the minimum structure for protein C activation is EGF456, while TAFI activation requires EGF3456.<sup>14–16</sup> In addition to the coagulation function, the TMD2 domain has mitogenic activity, although the exact repeats needed for this activity is unknown.<sup>17,18</sup> Next, the TMD3 domain is a serine/threonine-rich domain which contains attachment

sites for chondroitin sulfate (CS).<sup>19,20</sup> There are two kinds of membrane TM, one with and one without CS.<sup>21</sup> The CS moiety of TM is important for the enhancement of protein C activation by the thrombin–TM complex.<sup>22,23</sup> The TMD4 domain anchors TM to the cell membrane and classifies TM as a type-I membrane protein.<sup>24</sup> The TMD5 domain is a small cytoplasmic tail region that plays a role in TM's ability to multimerize.<sup>25,26</sup>

### Circulating Thrombomodulin in General

In addition to expression as a membrane protein on the cell surface, fragments of TM are also found circulating in the blood,<sup>27</sup> urine,<sup>28</sup> and other biofluids.<sup>29</sup> These fragments of TM lack the transmembrane domain and are known as soluble TM (sTM). They are derived from membrane TM by cleavage via either proteolysis or chemical and physical stress (**Fig. 1B**). The sTM consists of fragments of different molecular weights whose presence can vary by disease.<sup>29,30</sup> Different levels of sTM are found in many diseases.<sup>31–33</sup> In addition, endothelial cells can release microvesicles (MVs) containing membrane TM (microvesicle-TM) which also contribute to circulating TM levels (**Fig. 1C**).<sup>34</sup> Understanding of TM release mechanism is critical to comprehend its significance and role in disease development.

Measurement of the levels of circulating TM has great potential as a biomarker for diagnosis and tracking of

different diseases. In this review, we summarize all these advances in three categories: (1) release mechanisms of circulating TM, (2) methods for measuring circulating TM in biological samples, and (3) correlation of circulating TM with diseases.

### Release (Shedding) of Thrombomodulin

In healthy humans, the levels of sTM are low (<10 ng/mL),<sup>35</sup> while high sTM levels are common in patients suffering from various diseases. The mechanism responsible for sTM release is complex and several mechanisms have been proposed and confirmed. Primarily, TM is shed from the cell by enzymatic and/or chemical cleavage. It is known that endothelial TM serves as a cellular substrate for proteolytic cleavage, frequently leading to its shedding as various forms of sTM. Also, chemical cleavage of membrane-bound protein can generate sTM. Increased plasma sTM level has been accepted as a sensible marker for endothelial damage.<sup>36</sup> In particular, the consistent elevation of sTM levels during pathologies is now widely regarded as an important circulatory biomarker for endothelial dysfunction and vascular risk assessment.<sup>37–39</sup> It has been shown that sTM levels correlate with disseminated intravascular coagulation (DIC), stroke, multiple organ failure and mortality.<sup>40–43</sup> In addition, TM mutation that causes a synthesis of TM with the decreased size of the transmembrane domain can also contribute to the high levels of sTM in plasma.<sup>44</sup> A new autosomal dominant bleeding disorder characterized by very high plasma levels of sTM has been reported, in which the *THBD* c.1611C > A (p.Cys537X) mutation in a heterozygous state was identified.<sup>45,46</sup> The mutated TM lacks the last three amino acids of the transmembrane domain and the cytoplasmic tail and is associated with an increase in sTM in the plasma. On the other hand, activated endothelium can release microvesicles (and exosomes) containing membrane TM (microvesicle-TM).<sup>47</sup> Overall, the mechanism responsible for TM shedding is complex and is not completely understood. Both the extracellular stimuli and a defect of synthesis of truncated TM contribute to the high levels of sTM in plasma. Understanding the mechanisms for TM shedding could help better understand underlying mechanisms of many diseases. This section summarizes various mechanisms for TM shedding known so far.

### Proteolytic Release of Soluble Thrombomodulin

Previous research focused primarily on the proteolytic release of soluble TM from cells, which exists in biological fluids such as plasma, urine, and synovial fluid.<sup>25–27</sup> Proteolytic release of TM is a process, by which TM is cleaved from the cell surface after being exposed to specific proteases.<sup>47</sup> It is known that sTM is generated by proteolytic cleavage by proteases released during disorders associated with vascular damage, which include infection, sepsis, and inflammation.<sup>48</sup> It is known that neutrophil-derived proteases,<sup>27,49</sup> rhomboids,<sup>50</sup> metalloproteinases,<sup>51,52</sup> and possibly also cytokines<sup>53–55</sup> can cleave TM from the surface of endothelial cells. An earlier study demonstrated that primed activated neutrophils are potent modulators of endothelial TM using an endothelial tissue culture system.<sup>49</sup> In particular, neutro-

phil derived elastase and cathepsin G caused rapid dose-related reduction of TM activity on endothelial cell surface. The full-length TM extracellular domain (ECD) has also been shown to be cleaved from the endothelial cell surface after incubation with the neutrophil protease elastase, cathepsin G, and proteinase 3.<sup>27</sup> In addition, TM CTLD can also be cleaved from the cell surface by matrix metalloproteinases (MMPs).<sup>55</sup> A recent research confirmed that TM is a specific substrate of a transmembrane serine protease known as rhomboid-like-2 (RHBDL2).<sup>56</sup> RHBDL2 cleaves TM at a site proximal to the transmembrane domain, resulting in release of the ECD.<sup>50</sup> Furthermore, several inflammatory processes are associated with a moderate but statistically significant increase of sTM levels in plasma due to the proteolysis of TM by different leukocyte-derived proteases (elastase and cathepsin).<sup>57</sup> In the case of cytokine-induced release of TM, a metalloproteolytic cleavage mechanism was proposed in which cytokine induces metalloproteinase expression.<sup>52</sup> Exposure of cytomix (tumor necrosis factor [TNF]- $\alpha$ , interleukin [IL]- $\beta$ , and interferon- $\gamma$ ) to model alveolar epithelium A549 cells, primary human small airway epithelial cells, and primary human alveolar epithelial type-II cells induced shedding of TM. The shedding of TM was blocked by the hydroxamic-based metalloproteinase inhibitors TAPI and GM6001, suggesting that shedding of TM is mediated by a metalloproteinase.<sup>52</sup> However, no specific metalloproteinase was identified for the cytokine-induced metalloproteolytic cleavage of TM yet. Overall, the proteolytic release of TM depends on specific enzymes which afford different fragments of TM. Reported enzymatic release mechanisms of TM are summarized in ►Table 1. The physiological and pathological relevance of sTM release with different fragments requires further investigation.

### Chemical Release of Soluble Thrombomodulin

sTM can also be generated by chemical cleavage of the membrane bound TM (►Table 1). It has been shown that reducing agents such as glutathione, dihydrolipoic acid, and acetylcysteine (nonprotein thiols) can effectively stimulate release of sTM into the cell culture medium of human aortic endothelial cells (HAECs).<sup>58</sup> The use of reducing agents to release sTM will inactivate TM. In addition, oxygen radicals are known to rapidly induce direct toxic effects on endothelial cells (cytolysis) in vitro at high concentrations. This endothelial cell cytotoxicity is closely related to an increase in sTM levels in the culture supernatant after treatment of endothelial cells with oxygen radicals.<sup>27</sup> It is well known that oxygen and other free radicals oxidize Met388 in TM, thereby reducing the activation of protein C by 90%<sup>59</sup> while not affecting activation of TAFI.<sup>16</sup> Therefore, sTM released by oxygen radicals may have its Met388 oxidized and thus have less protein C activation activity as well. Furthermore, lysophosphatidic acid (LPA), a bioactive lipid mediator, is present during endothelial damage or injury. Treatment with LPA leads to shedding of the lectin-like domain of TM in HUVECs.<sup>55</sup> Currently, there is no report on chemical release of sTM with different fragments in vivo and its pathological relevance, which requires further investigation.

**Table 1** Proteolytic and nonproteolytic release of membrane bound TM

Release mechanism		Source	sTM (MW)	References
Enzymatic	Metalloproteinases	HUVEC	60 kDa	51
	Neutrophil derived proteases	HUVEC	56 kDa NA	27,49
	Rhomboids	Keratinocytes	90 kDa	50,56
Cytokine	TNF- $\alpha$	HUVEC	NA	54
	Cytomix (TNF- $\alpha$ , IL-1 $\beta$ , and Interferon- $\gamma$ )	Lung epithelial cells	NA	52,53
Chemical	Glutathione	HUVEC	NA	58
	Lysophosphatidic acid	HUVEC	63 kDa	58
	Oxygen radicals	HUVEC	56 kDa NA	27,49
	H <sub>2</sub> O <sub>2</sub>	HUVEC	NA	57
Physical	Cyclic strain	HUVEC	NA	62
Microvesicles	Monocyte (LPS)		NA	67
	Blood (Baboon after severe heatstroke)		NA	68
	Blood (SIRS patients)		NA	69
	HUVEC (cyclic strain)		NA	62
TM mutation	Blood and COS-1 cells		NA	44–46,76

Abbreviations: IL, interleukin; LPS, lipopolysaccharide; MW, molecular weight; NA, not available; sTM, soluble thrombomodulin; TNF, tumor necrosis factor; HAEC, human aortic endothelial cell; SIRS, systemic inflammatory response syndrome

### Physical Release of Soluble Thrombomodulin

Proteolytic and chemical release are the main contributors of sTM in the blood. However, physical force from the blood flow also causes sTM release from endothelial cells. It is known that blood flow-associated hemodynamic forces, such as cyclic strain (stretch) and shear stress, affect endothelial-dependent regulation of vessel homeostasis.<sup>60</sup> The effect of hemodynamic forces on endothelial TM expression has been investigated.<sup>61</sup> It was found that physiologic hemodynamic forces (cyclic strain) causes TM release from endothelial cells. The effects of equibiaxial cyclic strain and laminar shear stress on TM expression and release was examined with HAECs in vitro.<sup>62</sup> As a result, physiologic cyclic strain could cause the release of sTM in a time-, dose-, and frequency-dependent manner. There was no proteolytic release of sTM observed as inhibition of either MMPs (GM6001) or rhomboids (3,4-dichloroisocoumarin) showed no effect on strain-induced sTM release. This study indicates the importance of physical force on TM expression and release in vivo, especially in pathological and surgical operation procedures which requires further study.

### Release of Microvesicle-Thrombomodulin

MVs, a population of extracellular vesicles ranging in size from 0.1 to 1  $\mu$ m, are released from the surface of cells by the process of outward membrane budding through a loss of calcium-dependent membrane phospholipid asymmetry and cytoskeletal rearrangement.<sup>63,64</sup> MVs are released from the cell surface in response to cellular activation or apoptosis and are found in blood circulation at low levels during normal physiologic conditions, but at elevated levels

in a variety of diseases.<sup>65,66</sup> In body fluids, they constitute reliable hallmarks of cell damage. Early work by Satta and coworkers demonstrated that LPS treatment increases TM activity on monocyte-derived MVs by up to 80%.<sup>67</sup> Coelevated TM and MVs levels in serum have also been observed during heat stroke in baboons.<sup>68,69</sup> A later work by Duchemin et al pointed to an influence of circulating MVs on the “TM resistance” of patients suffering from myeloproliferative neoplasm.<sup>70</sup> MV-TM release from activated endothelium via endothelial MVs has been observed.<sup>71</sup> It was reported that endothelial injury releases MV-TM and MVs presenting other cell-specific surface antigens in the pathogenesis of sepsis.<sup>34</sup> They found that amount of the MV-TM was increased significantly in severe sepsis patients versus those in healthy controls, suggesting that it may play a role in the progression of sepsis-induced DIC. In another study, significantly elevated levels of MV-TM was isolated from HUVECs following physiologic cyclic strain.<sup>64</sup> Recently, MV-TM has been examined as potential biomarkers in sepsis,<sup>72</sup> cirrhosis,<sup>73</sup> and hepatocellular carcinoma (HCC).<sup>74</sup> The biological activity of MV-TM is still unclear but is speculated to affect vascular homeostasis. Therefore, a clearer understanding of how MV-TM is regulated within the vascular endothelium by physiological and pathological factors is of significant interest.

### Thrombomodulin Mutation and Shedding

TM mutations impair its function and are related to diseases development.<sup>75</sup> TM mutations are also associated with high levels of plasma sTM.<sup>44–46,76</sup> To date, two TM mutations have been demonstrated to cause high levels of possessed plasma

sTM. *THBD* Cys537Stop is the first identified TM mutation that arises from a premature stop codon at Cys537, resulting in truncation of TM within the transmembrane domain<sup>45</sup> (►Fig. 1B). It was found that each affected individual possessed plasma sTM levels > 100-fold higher than that normally observed. The mechanism by which the TM Cys537Stop is more readily released from the cell surface is still not fully understood, but may be associated with decreased membrane stability or increased susceptibility to proteolysis from membrane or plasma proteases.<sup>45,46</sup> A recent study by Westbury et al identified a novel TM mutation (*THBD* pPro496Argfs\*10) that results in a stop gain that causes synthesis of a TM variant truncated at the membrane-proximal C-terminal region of the extracellular domain<sup>76</sup> (►Fig. 1B). This truncated TM variant is therefore presumably no longer membrane localized and is instead secreted directly into the bloodstream, resulting in plasma sTM levels >100-fold higher than normal. These two mutations have been demonstrated to cause TM-associated coagulopathy that was first described in a family exhibiting abnormal bleeding that could not be attributed to known coagulation disorders by routine laboratory analyses.<sup>77</sup>

### Measurement of Circulating Thrombomodulin and its Activity in Biological Samples

Circulating TM exists either as sTM cleaved from membrane TM or MV-TM that is membrane TM released from cell membrane. Therefore, different methods are used to quantify their concentrations in biological samples. The level of sTM has been examined as a parameter of disease severity and progression. However, determination of whether sTM levels change between healthy and patients may have mixed results in certain diseases. Alternatively, TM indexes, which compares sTM and albumin levels in serum or other biofluid, have been used.<sup>78,79</sup> In addition, sTM concentration and TM activity are measured in biological samples and are used together for various diseases. In this section, the methods for quantifying sTM and MV-TM concentration and their activity are discussed in detail.

### Methods for Quantification of Soluble Thrombomodulin in Biological Samples

The most common techniques used to measure the protein levels of sTM are enzyme immunoassays (EIA) and enzyme-linked immunosorbent assays (ELISA). In addition, western blot and high-performance liquid chromatography (HPLC) methods are also used to quantify sTM concentration in biological samples. This section summarizes common methods for detecting and measuring sTM concentrations in biological samples (►Table 2).

#### Enzyme Immunoassays/Enzyme-Linked Immunosorbent Assays

EIA and ELISA methods are the most common ways to measure the concentration of sTM (►Supplementary Table S1). The detection limits can reach the pg/mL range but most often read in the low ng/mL range. Another advantage is the need for little sample preparation before analysis. In theory,

only sTM should be binding to the detecting or capturing antibodies and all other molecules are washed away and thus undetected. This allows for the immunoassays to handle complex samples such as plasma and urine. So far, many ELISA kits have been developed and are commercially available now (►Supplementary Table 1). These ELISA kits use biotin- and horseradish peroxidase (HRP)-labeled anti-TM antibodies or biotin-labeled detection antibodies to detect the sTM in serum, plasma, cell culture supernatant, tissue, or other fluids. However, there is no information available related to the specificity of TM domains for all these ELISA kits. If the presented sTM fragments do not contain the specific domain recognized by the antibodies, they will not be detected and quantified. In addition, to the reviewers' knowledge, no manufacturers of the commercial ELISA kits provide proof that the dose response for each of the sTM fragments is identical. Also, the identity of the antibodies used in the kits is often not disclosed, not even if they are monoclonal or polyclonal. Another issue is that the different suppliers offer very different levels of information on specificity, validation, and reproducibility. Therefore, the interpretation of changes in levels of sTM always needs to be cautious since the change of sTM fragments may cause ELISA response without the change of the overall level of sTM released.

#### Western Blot

Western blot is another antibody-based assay that is used to identify the presence of sTM in samples. In general, the initial gel electrophoresis step separates proteins based on their molecular weights. Transferring the separated protein to a membrane and probing with antibodies against sTM allows for the identification of sTM subspecies. The major advantage of using western blot is the ability to determine different molecular weight species of sTM if they all contain a fragment that can be recognized by an antibody. While the ability to see the different sTM subspecies of TM is helpful, western blot is not the best for gaining quantitative information. In addition to pictorial data, western blot data are represented as a ratio of the protein of interest to a loading control. Thus, western blot offers semiquantitative and most importantly qualitative information.

#### High-Performance Liquid Chromatography

HPLC offers the benefit of obtaining both quantitative and qualitative data at once. Detection limits of HPLC analysis with a UV-Vis detector can be similar to those of EIA/ELISA and reach the low ng/mL range.<sup>30</sup> Size exclusion chromatography allows for separation and identification of different molecular species of sTM. Molecular weights can be determined by comparing retention times of detected subspecies to those of standard proteins of known molecular weight. This gives the advantage of identifying molecular subspecies of sTM and their concentrations in the sample. However, the main disadvantage is that the sample needs to be pure sTM protein. The sTMs must first be isolated from the more complex sample using a method such as immunoprecipitation. The reasoning behind this is that other proteins could be coeluted with the sTM subspecies and give false readings.

**Table 2** Methods for measuring sTM in biological samples and diseases

Method	Sample	Disease(s)	Reference(s)
EIA	Plasma	Atherosclerosis, diabetes, DIC, sepsis	40,111,116
	Serum	Atherosclerosis, diabetes	127,129
	Urine	Diabetes	127
	Cerebral Spinal Fluid	Multiple sclerosis	78
ELISA	Plasma	ARDS, CAP, CHD, COVID-19, diabetes, HUS, hypertension, preeclampsia, lupus, multiple sclerosis, SARS, sepsis, stroke, TTP	43,53,91,93,99,100 104,105,119–121,128,148–150 159–161,192
	Pulmonary edema fluid	ARDS	53
	Serum	Lupus, multiple sclerosis, sepsis	78,95,106
HPLC-UV/Vis	Purified protein	Diabetes	30
Western Blot	Protein extract	Diabetes, transplant	193,194

Abbreviations: ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; CHD, coronary heart disease; COVID-19, novel coronavirus disease 2019; DIC, disseminated intravascular coagulation; EIA, enzyme immunoassays; ELISA, enzyme-linked immunosorbent assays; HPLC, high-performance liquid chromatography; HUS, hemolytic uremic syndrome; SARS, severe acute respiratory syndrome; TM, thrombomodulin; TTP, thrombotic thrombocytopenic purpura; UV/Vis, Ultraviolet-visible

Another disadvantage is the need for method development and column selection and availability. Developing methods for HPLC is more time consuming and complicated than those for ELISA and western blotting. Finally, HPLC analysis under nonreducing and nondenaturing conditions could not provide the sequence information of sTMs.

#### Measurement of Microvesicle-Thrombomodulin in Biological Samples

Flow cytometry is a conventional analytical technique for measuring physical and chemical characteristics of a population of cells or particles. In general, cell or particle surfaces are often labeled with fluorescent markers with defined excitation and emission wavelengths. Cells or particles are then quickly examined, and the data gathered are processed by a computer software. TM-presenting endothelial MVs were found in sepsis-induced DIC.<sup>34</sup> TM-presenting endothelial MVs were measured by flow cytometry.<sup>72–74</sup> Various MVs from different cells were labeled with different antibodies. Annexin V, anti-CD146 antibody, and anti-CD141 antibody (BD Biosciences) were used to stain the endothelial MVs. Specifically, Annexin V, anti-CD146 antibody, anti-CD141 antibody, and antiCD201 antibody (BD Biosciences) were used to stain the microvesicles. Endothelial MVs were defined by detecting annexin V and CD146 on the vesicle surface. TM-presenting endothelial MVs were defined by detecting annexin V, CD146, and CD141 on the particle surface.<sup>34</sup> It should be pointed out that there is no method developed so far to quantify the mass of TM-presenting MVs compared with freely circulating sTM, which is needed to evaluate its physiological and pathological relevance.

#### Measurement of the Activity of Circulating Thrombomodulin in Biological Samples

Membrane TM has many biological activities which depend on its different domains and expression by different types of

cells.<sup>47</sup> A variety of sTMs are released from membrane TM. It is important to know whether the sTM fragments have intrinsic activities. In the first report of sTM, Ishii and Majerus observed that sTM is less active than cellular TM in activating protein C.<sup>28</sup> Later studies measured the cofactor activity of isolated sTM from plasma, and found that the protein C activity was 30 to 50% compared with that of cellular TM.<sup>28,30,35,80</sup> Isolated human urinary sTM also shows protein C activation in human plasma.<sup>81</sup> As mentioned earlier, the minimum binding domain of TM for protein C activation is EGF456,<sup>14–16</sup> therefore, measurement of protein C activation is limited to the sTM containing EGF456 only. Previous studies measured the activity of sTM in biological fluids had not been investigated systematically under physiological or pathophysiological conditions. Therefore, the physiological and pathological significance of circulating and urinary sTM is presently unclear, which deserves future deeper research.

Measurement of the level of circulating sTM by immunological assays can be used to indicate endothelial-cell damage; however, it is not enough to fully evaluate certain diseases.<sup>82</sup> In addition, the use of sTM levels as a marker of endothelial injury is complex in certain patients like children, since it is physiologically increased during the first years of life.<sup>83</sup> Schneider et al analyzed the variations of sTM activity (TMA) and sTM antigen levels (TMag) in plasma of children with autologous and allogeneic bone marrow transplantation (BMT) and evaluated the ratio of TMA/TMag, since they observed that it was independent of age in healthy children.<sup>84</sup> In brief, TMA levels were measured on the STA-R analyzer (Diagnostica Stago, Asnières, France) using a chromogenic assay based on the ability of sTM to activate protein C after incubating with thrombin, protein C, polybrene, and a fibrin polymerization inhibitor. The activity was monitored with an activated Protein C (APC) substrate (CBS 4246) at 405 nm. It was found that the ratio of TMA/TMag could

constitute a marker for an early discrimination of children with high risk of complications during allogeneic BMT. Another study by Rousseau et al demonstrated that the measurement of plasma TMa and TMag could provide best discrimination between preeclampsia and normal pregnancy.<sup>85</sup> It was found that TMag and TMa levels increased in normal pregnancy but a significant increase was observed in preeclampsia which could be due to a more pronounced injury of the endothelium than in normal pregnancy. The TMag and TMa levels were also used to assess the prognosis of acute myocardial infarction.<sup>86</sup>

### Circulating Thrombomodulin in Diseases and Medical Procedures

As mentioned above, shedding of sTM and subsequent increased levels of sTM is mainly associated with endothelial injury or damage. Therefore, many diseases show high level of sTM in serum, urine, and other biofluids. Measurement of levels of sTM in serum, urine, and other biofluids are often taken for disease diagnostic and development monitoring, as well as therapeutic monitoring. Circulating sTM levels have been measured in many diseases and medical procedures, such as infectious disease, cardiovascular disease, diabetes, hypertension, obesity, immune diseases, surgical operation, transplantation, and hemodialysis (HD). Most diseases show high levels of circulating sTM, while some diseases show lower than base levels of circulating sTM. The majority of sTM levels are measured in either serum or plasma. The levels of sTM in plasma and in serum often cannot be compared directly often. If the detection method uses an enzyme, then ethylenediaminetetraacetic acid (EDTA) might not be the best choice, since it can inhibit enzyme activity. It should also be pointed out that sTM level alone cannot be used for clinical decision. Other biomarkers are often monitored with sTM as well. This section discusses the correlation of the circulating TM and (1) diseases, (2) surgical operation and intervention, and (3) HD in detail. The sTM levels and major diseases are summarized in ► **Table 3**.

### Circulating Thrombomodulin in Diseases

#### *Infection and Lung Diseases*

Acute lung injury and acute respiratory distress syndrome: the pathogenesis of acute respiratory distress syndrome (ARDS) is linked to a series of inflammation reactions that lead to the accumulation of neutrophils in the lungs<sup>87</sup> which causes endothelial cell damage in the lungs.<sup>88</sup> The lungs are rich in TM and have one of the highest levels of TM among human organs.<sup>89,90</sup> Since the pathogenesis and clinical displays of ARDS are closely linked to endothelial cell damage, sTM has been explored as a possible biomarker for disease severity and progression. It has been shown that patients with ARDS or those who are at risk for developing the condition have increased sTM levels in plasma and pulmonary edema fluid.<sup>53</sup> Patients already diagnosed with ARDS with more severe complications were seen to have higher levels of sTM compared with those who had less severe manifestations.<sup>85</sup> Also, patients who died of complications

due to ARDS had significantly higher levels of sTM compared with those who survived.<sup>91</sup> In addition to increased plasma levels of sTM, it has also been shown that lung sections of ARDS patients had lower expression of TM compared with healthy patients.<sup>92</sup> This observation agrees well with the trend of seeing increased blood levels of sTM in ARDS patients. Overall, plasma sTM level can be a useful predictor for the onset of ARDS, as it proves to be a good addition to other clinical markers and tests to help determine disease severity.

Novel coronavirus disease 2019: The novel coronavirus disease 2019 (COVID-19) is a new infectious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) which has been producing devastating effects not only on human health but also on the global economy. Clinical studies showed that endothelial vascular injury plays a key pathogenetic role in the development of COVID-19-associated coagulopathy, especially among intensive care unit (ICU)-hospitalized patients.<sup>93</sup> Markers of endothelial cell injury could be used to identify the disease severity and mortality. Two recent findings suggest that the plasma level of sTM is highly correlated with survival among COVID-19 patients and measuring sTM levels might aid in managing patients.<sup>93,94</sup>

A report by Goshua et al from Yale University examined blood samples of COVID-19 patients (those critically ill in an ICU) and others receiving care but in a non-ICU unit) and disease-free volunteers.<sup>93,95</sup> Specifically, they compared biomarkers of endothelial cell and platelet activation, including sTM, von Willebrand's factor (vWF) antigen, soluble P-selectin, and soluble CD40 ligand, as well as coagulation factors, endogenous anticoagulants, and fibrinolytic enzymes. They found that markers of endothelial cell and platelet activation were significantly elevated in patients, ICU patients versus non-ICU patients. In particular, ICU patients with high sTM levels were discharged from hospital to a significantly lesser degree than those with lower sTM levels, while in a total patient cohort and ICU-only cohort, high sTM levels were consistently associated with decreased survival probability. From the pathophysiological perspective, elevated sTM concentrations likely reflect direct endothelial cell damage, therefore the concentration of sTM in the blood might be the surrogate for the degree of endothelial injury in COVID-19. Moreover, as a surrogate marker of endothelial injury, sTM also seems to provide prognostic information in this population. In another study, Jin et al analyzed sTM and other biomarkers like vWF and P-selectin in COVID-19 patients.<sup>94</sup> They also found that the level of sTM was higher than health controls and sTM level was correlated with disease severity. Overall, these studies demonstrated that endothelial damage is present in a wide range of COVID-19 patients, particularly as people become critically ill. Furthermore, sTM levels could be used a biomarker to identify which patients are most likely to progress toward critical illness and possibly death, as these patients might benefit from closer monitoring and possibly earlier intervention.

Pneumonia, community-acquired pneumonia: in the pathogenesis of community-acquired pneumonia (CAP),

**Table 3** sTM and other markers in major diseases

Disease	Sample(s)	sTM Level ↑ (increase/ ↓ decrease)	Other markers	Reference(s)
AAA	Plasma	↑	Fibrinogen, D-dimer, CRP	86,108,195
ARDS	Edema fluid, plasma	↑	vWF, P/E-selectin	53,91,196,197
Atherosclerosis	Plasma, serum	↑	CRP, proinflammatory cytokines, fibrinogen	111,192,198
CAP	Plasma	↑	PCT, CRP, copeptin	99,199
Cardioembolic stroke	Plasma	↑	D-dimer, TAT, vWF	43,167,200
CHD	Plasma	↓	Insulin, GHS-Px, TNF-α	111,201
COVID-19	Plasma	↑	vWF, P-selectin	93,94
Diabetes	Plasma, serum, urine	↑	HbA1c, AGEs,	30,112,121–123,202
DIC	Plasma	↑	TAT, PIC, D-dimer	40,41,101,116,117
HUS	Plasma	↑	MMP-3, sTNFRII, sIL-6R	119,120,203
Hypertension	Plasma, serum	↑	CRP, PAI-1	119,129,130,204
Lupus	Plasma, serum	↑	Anti-dsDNA, ANAs	148,193,205
Multiple sclerosis	Cerebral spinal fluid, plasma	↑	Oligoclonal bands, antibodies (anti-MOG, anti-AQP-4)	78,79,150,206
Obesity	Plasma	↑	NA	154
Preeclampsia	Plasma	↑	sFLT-1, sEng	158–160,207
Sepsis	Plasma, serum	↑	CRP, PCT, proinflammatory cytokines	40,92,93,104,105
SARS	Plasma	↑	Nucleocapsid protein	100,208
TTP	Plasma	↑	Troponin I, anti-vWFPC antibody	119,209,210

Abbreviations: AAA, abdominal aortic aneurysm; ACI, acute cerebral infarction; AGEs, advanced glycation end products; ANAs, antinuclear antibodies; AQP-4, aquaporin-4; ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; CHD, coronary heart disease; COVID-19, novel coronavirus disease 2019; CRP, C-reactive protein; DIC, disseminated intravascular coagulation; GHS-Px, glutathione peroxidase; HbA1c, hemoglobin A1c; HUS, hemolytic uremic syndrome; MMP-3, matrix metalloproteinase 3; MOG, myelin oligodendrocyte glycoprotein; PAI-1, plasminogen activator inhibitor-1; PCT, procalcitonin; PIC, plasmin-α2-plasmininhibitor complex; SARS, severe acute respiratory syndrome; sEng, soluble endoglin; sFLT-1, soluble FMS-like tyrosine kinase; sIL-6R, soluble interleukin-6 receptor; sTNFRII, soluble tumor necrosis factor receptor type II; TAT, thrombin-antithrombin complex; TNF-α, tumor necrosis factor α; TTP, thrombotic thrombocytopenic purpura; vWF, von Willebrand's factor; vWFPC, vWF cleaving protease.

there is a high inflammatory response which causes damage to the endothelium leading to coagulation activation and the release of inflammatory mediators.<sup>96</sup> Common assessments of disease severity are the pneumonia severity index (PSI), used to identify low-risk patients or those who can continue to outpatient care, and the CURB65 score which is used to determine high-risk patients.<sup>97,98</sup> The measurement of related biomarkers has also been added to supplement the scores of these two assessments. Recently, plasma sTM levels have been shown to significantly increase in patients with worsening CAP.<sup>99</sup> Also, sTM levels used in combination with either the PSI or CURB65 score allowed for an increase in accuracy in prognosis evaluation. These results indicate that sTM level is useful in the evaluation of the severity and outcome of CAP in the emergency department.

Severe acute respiratory syndrome: SARS is a viral respiratory illness caused by a coronavirus called SARS-associated coronavirus (SARS-CoV). Liu et al evaluated classic plasma markers of endothelial injury tissue-type plasminogen acti-

vator (t-PA) and sTM in patients with SARS.<sup>100</sup> They found that sTM and tPA had significantly elevated levels in SARS patients in comparison to controls. Furthermore, patients who died had extremely high levels of sTM (1.01 nmol/L). Increased plasma concentrations sTM in patients with SARS suggest the possibility of endothelial injury. This observation is consistent with the new coronavirus disease COVID-19 which also shows higher sTM level in afflicted patients.<sup>93,94</sup> The sTM level may not only provide a useful treatment and prognostic index but also allow a further understanding of the pathological condition of the disease.

Sepsis: a key role of the pathogenesis of sepsis are uncontrolled inflammatory responses which causes damage to endothelial cells.<sup>101</sup> sTM levels have been used as diagnostic, prognostic, and mortality indicators in patients with sepsis.<sup>102,103</sup> Multiple studies have shown a positive correlation between sTM levels and the severity of sepsis in both adult and pediatric patients.<sup>40,93,104,105</sup> It has even been shown that sTM was better at predicting severe



complications, such as multiple organ dysfunction syndrome (MODS), over accepted risk and prognosis assessment methods such as SOFA and APACHE II.<sup>105</sup> Additionally, patients who died of sepsis had higher levels of plasma sTM levels compared with those who did not.<sup>40,106</sup> From these studies, it can be inferred that sTM level can be used to track the severity of sepsis and possibly how the patient's disease will progress. Early diagnosis and treatment of people undergoing septic shock (SS) is crucial for their survival and can help reduce mortality rates.<sup>96</sup> MVs have been largely studied as potential biomarkers in SS. A recent case-control study found the trend of various MV subtypes during SS to evaluate their possible association with severity of illness and sepsis-related complications (DIC and acute kidney injury [AKI]).<sup>72</sup> Specifically, septic patients showed higher levels of all MVs considered compared with controls. TM + MV were significantly lower in more severe sepsis.

### Cardiovascular Diseases

There is increasing experimental evidence that endothelial dysfunction represents an important component of cardiovascular disease (CVD) and stroke. In many cases, TM shedding from endothelial cells of arteries and veins contribute to certain amount of circulating sTM. Therefore, the levels of circulating sTM are highly related with CVD and stroke.

**Abdominal aortic aneurysm:** abdominal aortic aneurysm (AAA) is a vascular disease in which endothelial dysfunction plays an important role.<sup>107</sup> Brunelli et al reported a significantly higher level of sTM in AAA patients associated with elevated homocysteine levels, a factor alleged to contribute to endothelial injury.<sup>86</sup> Another study evaluated sTM concentration in patients undergoing a surgery for the repair of AAA and examined its association with disease severity reflected by aneurysm size.<sup>108</sup> It was found that sTM concentrations were significantly increased in AAA patients compared with healthy volunteers. This study demonstrated a significant increase in concentration of sTM in the blood of AAA patients which is in line with previous findings.<sup>81</sup> In particular, sTM concentration remained elevated in the subgroup of patients without clinical manifestations of atherosclerosis, suggesting that an increased sTM level is an independent feature of AAA rather than an effect of atherosclerotic alteration which commonly occurs among AAA patients.

**Acute myocardial infarction:** several studies have indicated an association between hemostatic markers and acute myocardial infarction. Öhlin et al reported that sTM antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy.<sup>109</sup> van Dreden et al studied plasma levels of 10 coagulation factors and analyzed the activity of plasma tissue factor (TFa), sTM, and procoagulant phospholipid in patients with acute myocardial infarction at the time of hospital admission.<sup>110</sup> It was found that plasma levels of TFa, sTM, and procoagulant phospholipid were significantly higher in cases of acute myocardial infarction than in healthy volunteers. In addition, patients with an unfavorable outcome during a 2-month follow-up had higher levels of TFa, sTM, and procoagulant

phospholipid. The association of the level of the activity of these three factors may provide a useful tool to assess the prognosis of acute myocardial infarction.

**Atherosclerosis:** TM is expressed in a variety of cells associated with atherosclerotic lesions. These include endothelial cells, foamy macrophages, spindle cells, intimal smooth muscle cells, and medial smooth muscle cells.<sup>18</sup> An early study showed that serum levels of sTM were significantly increased in patients with an atherosclerotic lesion versus healthy controls.<sup>100</sup> A further significant increase was seen in patients who had multiple lesions.<sup>100</sup> It was also found that sTM positively correlated with vWF and was more sensitive to determining wide-spread disease than vWF. sTM levels could also be used as a predictor for developing atherosclerosis. A large cohort study found that patients whose plasma sTM levels were raised had a higher chance of developing carotid atherosclerosis.<sup>111</sup> It has also been shown that plasma sTM levels could be used as a biomarker to help determine if a patient with ischemic heart disease would develop a cardiovascular end point.<sup>112</sup> Patients who had hypercholesterolaemia, but no signs of atherosclerosis or other cardiovascular complications, were not seen to have any difference in levels of plasma sTM.<sup>113</sup> This indicates that sTM may not be a good predictor of atherosclerosis but may be useful for determining/monitoring disease severity.

**Coronary heart disease:** the relationship between plasma sTM and the relative risk of coronary heart disease (CHD) has been evaluated, and levels of sTM were seen to be inversely associated with the risk of CHD.<sup>111</sup> It was found that individuals with a high level of sTM were associated with a significant reduction in the relative risk of coronary heart disease events. Combinatorial analysis of sTM and soluble intercellular adhesion molecule-1 (sICAM-1), a known biomarker for CHD, provides a more specific assessment of CHD risk. In another large prospective case-cohort study, it was found that sTM did not predict future coronary events in apparently healthy, middle-aged patients.<sup>114</sup> Although not predictive, increased sTM concentrations on the incidence of coronary events among apparently healthy patients do not exclude the potential significance of sTM-regulated mechanisms in the pathophysiology of atherothrombotic heart disease.

**Disseminated intravascular coagulation:** biomarkers of endothelial damage have been previously seen to increase in DIC patients, including sTM, tissue type plasminogen activator (t-PA), and plasminogen activator inhibitor-1 (PAI-1).<sup>115</sup> Patients with DIC were shown to have nearly double the amount of plasma sTM levels compared with healthy controls. Plasma sTM levels were also significantly higher for patients whose condition worsened to develop organ failure or death.<sup>41,101,116,117</sup> sTM was better than t-PA, PAI-1, and vWF at correlating with the development of organ failure.<sup>118</sup> In addition, endothelial injury releases microparticle TM in the pathogenesis of DIC.<sup>34</sup> It was found that number of microparticle TM was increased significantly in both severe sepsis patients and controls. With an additional increase in International Society of Thrombosis and Hemostasis (ISTH) DIC score, the study suggests that the specific

bioactivity of microparticle TM may play a role in the progression of sepsis-induced DIC. Therefore, sTM levels and microparticle TM can be used as biomarkers of DIC.

Thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS): the plasma sTM levels were measured in patients with thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) and in healthy volunteers to examine the relationship between the occurrence of hemostatic abnormality or vascular endothelial cell injury and patient outcome.<sup>119</sup> It was found that the plasma sTM levels in TTP/HUS patients were significantly higher than in healthy volunteers. Furthermore, the plasma sTM levels were significantly higher in patients who died than in patients who survived. These findings suggest that the outcome of TTP/HUS is related to vascular endothelial cell injury and that plasma sTM levels may be useful markers for fatality of TTP/HUS patients who survived and those who died. On the other hand, increased plasma sTM levels were reported in HUS patients.<sup>119,120</sup> Since sTM is probably excreted via glomerular filtration, the impaired glomerular function present in HUS could contribute to the increased circulating sTM levels found in patients.

#### *Diabetes Mellitus*

With both endothelial damage and dysfunction at play in diabetes mellitus (DM), a significant amount of research has been performed on how sTM levels change in DM. The overall trend is that sTM levels are increased in the biological fluids of diabetic patients.<sup>30,112,121–125</sup> Levels were also shown to have a weak positive correlation of disease duration and number of complications.<sup>112,122,123</sup> However, no difference was found between type-I and -II diabetic patients.<sup>122</sup> It has also been shown that high sTM levels were associated with increased risk for all-cause mortality and CVD deaths.<sup>126</sup> Plasma and urinary sTM levels were also positively correlated with urinary albumin, a marker for nephropathy.<sup>122,127</sup> The subspecies profile of plasma sTM was also found to be different in diabetic patients compared with healthy person. In diabetic patients, more of the 74 and 48 kDa TM fragments were found, while five other fragments were found to be unchanged.<sup>30</sup> These different TM fragments formation indicates a complicated TM release mechanism, which deserves a further investigation.

#### *Hypertension*

Earlier studies on pulmonary hypertension found that the pulmonary vascular endothelium is deficient in anticoagulant proteins like TM. A later study with patients with chronic thromboembolic pulmonary hypertension (CTEPH) showed significantly lower sTM levels than that in the control group.<sup>126</sup> In contrast, there is no difference of the plasma sTM concentration of patients suffering from acute pulmonary thromboembolism (APTE). After patients underwent pulmonary thromboendarterectomy, the sTM concentration increased significantly. In the CTEPH group, the plasma sTM concentration was negatively correlated with pulmonary arterial pressure and total pulmonary resistance.<sup>126</sup> Another study confirmed that plasma sTM level was elevated in

scleroderma associated pulmonary hypertension compared with scleroderma controls and healthy controls.<sup>128</sup> It is known that circulating levels of sTM are elevated in patients with hypertension in proportion to the severity of the vascular damage.<sup>129</sup> A cross-sectional study with patients with essential hypertension suggested that circulating levels of sTM were elevated in hypertensive patients as compared with normotensive subjects and that the sTM level may be a molecular marker of the latent progression of atherosclerosis in hypertensive patients.<sup>130</sup>

#### *Kidney Disease*

The excretion of sTM from kidney will affect the concentration of the plasma sTM and urinary sTM. Therefore, kidney disease will affect the concentration of the plasma sTM and urinary sTM accordingly. In patients experiencing renal failure caused issues where endothelial cell damage does not occur, plasma sTM is raised. There is also a positive correlation with serum creatinine, a staple biomarker of renal function, and a negative correlation with creatinine clearance.<sup>131</sup> However, many kidney diseases do cause endothelial cell damage. Elevation of plasma sTM level and different sTM fragments have been confirmed in urine to related kidney diseases in several studies.<sup>132–135</sup> Chronic kidney disease (CKD) is linked with coagulation and inflammation dysregulation where TM is a key player.<sup>136,137</sup> For patients experiencing CKD, serum sTM levels were found to be positively correlated with disease severity after stage 3. The rise is thought to be due to increasing complications of CKD, such as atherosclerosis. In addition to the usual relation with serum creatinine, serum sTM levels were found to be negatively correlated with the estimated glomerular filtration rate. This may also be a cause for the increase in sTM levels.<sup>133</sup>

#### *Liver Diseases*

The liver regulates the most chemical levels in the blood by breaking down or converting certain substances. There are considerations on liver function as predictors of sTM levels. Therefore, there is a correlation between sTM levels and liver diseases as well. Plasma sTM levels were often evaluated in patients with liver diseases.<sup>138–141</sup> TM expression in hepatic endothelial cells are highly affected in liver diseases like viral hepatitis<sup>134</sup> and liver damage<sup>141</sup> which also cause sTM release. Overall, liver enzymes could be modulators of sTM and sTM levels as well. The increase in plasma sTM levels in liver disease may be due to defective hepatic degradation of the circulating sTM. On the other hand, higher level or activity of liver enzymes may cause decreased plasma sTM levels. It is not known how liver function and dysfunction influence sTM levels. The plasma sTM levels and liver diseases deserve further mechanistic study. MVs have been proposed as potential biomarkers of cirrhosis. A recent study characterized circulating plasma MVs profile in patients with decompensated cirrhosis and AKI.<sup>73</sup> They found that patients with cirrhosis with AKI had a significantly higher level of total MVs compared with patients with cirrhosis without AKI but comparable severity of underlying liver

disease. They concluded that AKI is responsible for the increased levels of MVs observed in patients with cirrhosis.

#### *Lupus, Systemic Lupus Erythematosus*

Common pathologic features that accompany systemic lupus erythematosus (SLE) are endothelial cell apoptosis, endothelial dysfunction, and inflammation.<sup>142–144</sup> A defining pathologic feature of SLE is widespread and recurring vascular lesions.<sup>145</sup> Markers for endothelial cell injury, like sTM, could be useful for helping determine the diagnosis or severity of the disease.<sup>146,147</sup> sTM levels as a whole are elevated in patients, both adults and juveniles, suffering from SLE.<sup>95,148</sup> TM levels also showed a positive correlation with disease activity and was stronger versus other markers such as E-selectin and sICAM-1.<sup>146,148–151</sup> Complications of SLE related with increasing sTM levels include nephritis, vasculitis, and central nervous system (CNS) lupus.<sup>146,152</sup> sTM levels were also useful in distinguishing between patients with active lupus nephritis (LN) or inactive LN.<sup>153</sup>

#### *Multiple Sclerosis*

Determination of whether sTM levels change between healthy and multiple Sclerosis (MS) patients has had mixed results. Some research groups have seen no change in serum sTM levels or sTM levels in cerebral spinal fluid (CSF).<sup>78,79</sup> However, even though serum sTM levels and CSF fluid sTM levels alone were not significantly different among groups, a difference was seen in TM indexes. TM index takes into account the sTM levels in serum and CSF and is compared with albumin levels in the serum and CSF. TM indexes were higher in relapsing MS and progressive MS groups compared with healthy patients. It was attributed the increase in index as a result of endothelial cell damage or deregulation of TM release in the brain microvascular endothelial cells.<sup>78</sup> A few studies though have found significant changes in sTM levels in patients with MS and even change among differing disease states.<sup>150</sup> These results indicate sTM can be used to determine disease severity as sTM levels rise with more severe varieties of MS.

#### *Obesity*

Obesity is a complex disease and has high risk of other diseases and health problems, such as heart disease, diabetes, high blood pressure and certain cancers. The plasma concentration of sTM is associated with obesity as well. A previous study investigated the plasma concentration of sTM in children and adolescents with obesity.<sup>154</sup> They measured plasma concentration of sTM, blood lipids profile, creatinine, and its clearance. They found that plasma concentration of sTM in the group with obesity was significantly higher than that in the control group. There was no significant association between sTM and age or sex. In addition, statistically significant correlation between sTM and body mass index (BMI) was observed in the obese group.

#### *Preeclampsia*

TM is present on syncytiotrophoblasts and the endothelium of the vasculature that covers the trophoblastic sur-

face.<sup>155,156</sup> TM is the main mediator of the anticoagulant system in the placenta.<sup>157</sup> Minakami et al first studied the plasma levels of sTM in preeclamptic women as compared with normal pregnant and nonpregnant women.<sup>158</sup> They found that the plasma levels of sTM were significantly elevated in preeclamptic women versus controls. Later studies also confirmed increased sTM levels of preeclampsia (PE) patients.<sup>159,160</sup> sTM levels also increase with each trimester in normal pregnancy which is made worse in PE complicated pregnancies.<sup>161,162</sup> Another observation was that plasma sTM levels began to significantly rise earlier in patients who would later develop PE by week 24 when compared with pregnancies that were uneventful by week 32.<sup>163</sup> The rise in sTM levels is thought to be mainly due to cleavage from the endothelial surface which is further supported by the finding that the placenta of PE patients expresses less TM on their endothelial surfaces versus normotensive patients.<sup>164</sup>

#### *Stroke*

Plasma sTM levels and vWF were often measured to check the risk of ischemic and hemorrhagic stroke.<sup>165</sup> Earlier study found no relationship between increased sTM concentration and the risk of brain infarction (BI).<sup>165</sup> However, a later study confirmed that sTM level was associated with lacunar stroke and asymptomatic carotid stenosis progression.<sup>166</sup> Since then, several studies have confirmed increased plasma sTM levels in stroke.<sup>43,167</sup> A study of patients with acute cerebral infarction (ACI) in Japan confirmed that sTM concentrations were correlated with the severity of ACI.<sup>167</sup> It was found that sTM concentrations at admission in patients with cardioembolic infarction were significantly lower than those of lacunar infarction. Although sTM concentrations serve as a useful marker for endothelial cell damage, they are decreased in patients with severe ACI, especially in atherothrombotic and cardioembolic infarctions. Lower sTM concentrations may play some important role in disease progression or in the recurrence following ACI, although the exact mechanism of this unique result should be clarified.

#### *Trauma-Induced Coagulopathy*

The emergency management of acute severe bleeding in trauma patients has been paid more attention in recent years. In particular, a prompt assessment of coagulation alterations is necessary and allows for immediate hemostatic resuscitation procedures.<sup>168</sup> Coagulopathic bleeding stems from a complex interplay among hemostatic and inflammatory systems which are characterized by a multifactorial dysfunction in major traumas. Anticoagulation is one of the main determinants of trauma-induced coagulopathy (TIC). Brohi et al found increased levels of circulating TM, along with decreased plasma levels of protein C within 1 hour from a traumatic event in patients with severe anatomical injury and tissue hypoperfusion.<sup>169</sup> TIC remains one of the most diagnostically and therapeutically challenging conditions. Measurement of pathophysiological alterations in TIC will facilitate better emergency management of TIC.

## Cancer

TM expression has been described in multiple cancer types on the endothelium and tumor cells.<sup>170,171</sup> It is known that TM exerts an influence on the metastatic capacity of cancer, with elevated TM expression conferring a positive predictive and prognostic factor.<sup>170</sup> The level of sTM has been evaluated for cancer metastasis and prognosis.<sup>172</sup> To clarify the correlation between sTM levels and clinicopathological parameters, the plasma sTM levels of primary soft tissue tumors (benign and soft tissue sarcoma [STS]) were measured before biopsy or treatment. It was found that STS tumors had significantly higher sTM concentration than benign tumors. These results demonstrated that a high level of sTM has the potential to be a significant predictor of metastasis and poor prognosis in STS patients. sTM is a candidate molecular marker for high metastatic potential and can be clinically useful for guiding therapeutic strategy which deserves future study. Portal vein thrombosis (PVT) is a common complication of hepatocellular carcinoma and is associated with a poor prognosis. Circulating MV-TM in plasma of patients with cirrhosis with and without HCC were evaluated for the possible contribution of MV-TM in PVT occurrence in HCC.<sup>74</sup> They found that patients with concomitant cirrhosis and HCC showed higher levels of MV-TM than patients with cirrhosis without HCC and healthy controls.

## Circulating Thrombomodulin in Surgical Operation and Intervention

Surgical operation and intervention can cause endothelial damages and thus lead to sTM release from the cells and tissues of the injured sites. Therefore, sTM levels were often measured related to the disease treatment and recovery. This section summarizes the sTM levels related to variety of surgical operations and interventions. The sTM levels in surgical procedures are summarized in **Table 4**.

sTM levels were assessed during cardiac catheterization procedure. Vielhaber et al conducted a prospective study in children by measuring sTM concentrations, along with thrombin generation before, at the end of and 24 hours after cardiac catheterization.<sup>170</sup> They found that sTM concentra-

tions increased significantly at the end of cardiac catheterization and returned to pretreatment levels 24 hours later. Data from this study indicate that increased sTM concentrations after cardiac catheterization are a sign of short-term endothelial damage. Endothelial damage caused by coronary artery bypass graft (CABG) procedure itself could contribute to bypass graft occlusion in the early postoperative period. A significant increase in sTM level during the first week post-CABG was observed.<sup>173</sup> This phenomenon might account for the increased risk of occlusion of bypass grafts at this moment of the postoperative period. Another recent study analyzed the association between levels of sTM and inflammation and described the possible explanations about association between sTM and postoperative complications.<sup>174</sup> They found that the levels of sTM increased during the first postsurgery week, and then decreased to levels similar to those recorded preoperatively. The transient increase in sTM during the first week after CABG was associated with an inflammatory response and leukocytosis. The levels of plasma sTM and inflammatory and myonecrotic markers in patients undergoing percutaneous coronary interventions (PCI) have been also evaluated.<sup>175</sup> Specifically, plasma levels of sTM, C-reactive protein (CRP), and creatine kinase and its MB isoenzyme were measured before and after PCI. As a result, sTM levels increased significantly after PCI, showing better correlation with inflammation than myocardial injury, indicating an endothelial origin.

## Circulating Thrombomodulin in Transplantation

TM has been hypothesized to play a role in graft rejection as increase in TM expression has been shown to lower the risk of xenotransplantation failure<sup>176</sup> and graft rejection.<sup>82</sup> A 1995 study explored how plasma sTM levels changed with reperfusion and if sTM levels could predict graft complications. It was observed that plasma sTM levels after the anhepatic phase were triple those of preoperative levels. Additionally, a large incidence of graft rejection or failure was seen when sTM levels were greater than 138 ng/mL.<sup>177</sup> This section describes sTM levels related to different transplantations. The sTM levels in transplantation are summarized in **Table 4**.

**Table 4** sTM in surgical procedures and transplantation

Surgical procedure/transplantation		Other markers	Reference(s)
Surgical procedure	Cardiac catheterization	Thrombin	211
	Coronary artery bypass graft (CABG)	IL6	173,174
	Percutaneous coronary interventions (PCI)	C-reactive protein (CRP)	175
	Bone marrow transplantation	sTM activity	53,55,84
Transplantation	Liver transplantation	Thrombin-antithrombin III complexes, protein C aminotransferase (AST), alanine aminotransferase (ALT)	177-179,184
	Renal transplantation	sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3, IL6, IL-8, TNF- $\alpha$ , CRP	182,212

Abbreviations: IL, interleukin; sTM, soluble thrombomodulin; sICAM, soluble intercellular adhesion molecule-1; TNF, tumor necrosis factor.

Liver transplantation can cause endothelial damage allowing sTM to serve as a marker during liver transplantation.<sup>178,179</sup> In addition, reperfusion injury causes damage to endothelial cells and leads to sTM release as well. Sido et al. evaluated intraoperative sTM as a marker of reperfusion injury in liver transplant recipients.<sup>177</sup> It was found that sTM levels were significantly elevated, as compared with healthy control patients, and remained unchanged at the end of the anhepatic phase. In addition, postreperfusion sTM levels correlated significantly with the early liver enzyme release (aspartate transaminase). These observations indicate that sTM is a marker of reperfusion injury which correlates with the early liver enzyme release and the accumulation of intrasinusoidal granulocytes. sTM level was used as marker for predicting early graft function in clinical liver transplantation.<sup>180</sup>

Renal transplantation can cause endothelial damage and dysfunction that may contribute to the hypercoagulable and inflammation states presents in renal transplant. A recent study assessed sTM, vWF, and IL-6 in renal transplant recipients (RTRs) and associated their plasma levels with primary cause of end-stage renal disease (ESRD) and allograft function.<sup>181</sup> They found that sTM and IL-6 could be used as potential markers for evaluating renal graft function. sTM was more related to the primary cause of chronic kidney disease (CKD) compared with vWF and IL-6. In addition, sTM and other serum biomarkers of endothelial dysfunction and low-grade inflammation were evaluated for renal replacement therapy.<sup>182</sup>

### Circulating Thrombomodulin in Hemodialysis

There have been clinical studies suggesting a correlation between increased sTM levels and vascular endothelial damage in patients undergoing HD. Very high plasma levels of sTM were considered to be associated with endothelial cell damage in addition to the presence of uremia.<sup>182</sup> The HD procedure alone is suspected for release by and damage to the endothelial cells, probably of result of hypoxia, complement activation, platelet activation, and a release of leukocyte proteases during HD. Numerous coagulation and fibrinolytic disorders appear in HD patients.<sup>181</sup> It was found that coagulation factors TFPI, sTM, and vWF were increased in HD patients.<sup>183</sup> sTM levels can be used as marker for monitoring HD procedure.

### Summary and Future Perspective

TM is a type-1 transmembrane glycoprotein expressed mainly on vascular endothelial cells which plays many biological functions. TM also circulates as sTM and MV-TM in biological fluids ranging from serum and urine to synovial fluid. sTM can be generated by physical stress, enzymatic cleavage, or chemical cleavage of the intact protein,<sup>28,50</sup> while MV-TM is shed from cell membrane as membrane fragments containing the membrane TM.<sup>35</sup> In addition, TM mutations also cause TM release.<sup>44-46,76</sup> The circumstances in generating sTM are different between endothelial cells reacting to extracellular stimuli and a congenital genetic mutation in the *THBD* gene. In normal physiologic condi-

tions, sTM circulates at a low concentration (<10 ng/mL) in plasma<sup>31,39</sup>; however, it is elevated in several pathologic conditions associated with endothelial dysfunction.<sup>34,66</sup> On the other hand, MV-TM levels in serum have also been observed during systemic inflammatory response syndrome in humans and during heat stroke.<sup>68,69</sup> Therefore, increased plasma sTM levels and MV-TM have been used to monitor diseases development and surgical operation, transplantation, and even predict mortality in patients such as COVID-19.

It is still unclear how sTM levels contribute to physiology and pathophysiology. It will totally depend on what fragments of the sTMs are as each domain of TM has distinct activity which may be generated under specific conditions. However, it is unknown if the release of sTM is a tightly regulated process in which specific domains are cleaved and released. There have been four,<sup>31</sup> six,<sup>184</sup> or seven<sup>30</sup> sTM fragments reported in plasma, suggesting multiple cleavage sites and different mechanisms due to endothelial cell damage in varying diseases. In addition, two forms of sTM were isolated from human urine in two separate studies.<sup>81,185</sup> Concerning the biological activity, sTM isolated from plasma showed the thrombin-mediated activation of protein C and the activity was 30 to 50% compared with that of cellular TM.<sup>186</sup> Also, the sTM fragments in plasma inhibit fibrinolysis through the activation of TAFI.<sup>187</sup> Characterization of these fragments by N-terminal sequencing revealed that one form encompasses the EGF repeats and retained the ability to bind thrombin. In contrast, the second fragment corresponded to the equivalent molecular weight for the N-terminal CTLD and failed to bind thrombin. Overall, the precise functional relevance and activity of sTM fragments and the mechanisms for sTM release are not fully understood, mechanistic and proteomic study about sTM fragments merit further investigation. Finally, the physiological and pathological relevance of different sTM fragments require further investigation.

Different methods are used to quantify sTM concentration in biological samples. EIA and ELISA methods are the most common ways to measure sTM in which an anti-TM antibody is used. The main question is if a single antibody can capture all fragments of sTM when multiple forms of sTM exist in the biofluids. However, it is an unanswered question. In addition, TM activity, like protein-C activation, is also measured in biological samples for various diseases, which is often used in conjunction with sTM concentration measurements. Again, since different domains of TM have different activities and many fragments of sTM exist, a single activity assay may not be adequate to evaluate sTM in different diseases. On the other hand, MV-TM activity has not been investigated. It is known that MVs have different membrane assembly from cell membrane<sup>188</sup> which may affect TM activity on the MVs. Therefore, further research is needed to investigate circulating TM concentration and their activity for both basic research and clinical applications.

### Conclusion

Overall, sTM levels are widely investigated in disease monitoring and diagnosis. However, preexisting/coexisting

conditions such as liver or kidney disease or both will affect plasma sTM levels after release from vascular endothelial injury.<sup>189</sup> The liver appears to be an important site of TM clearance as confirmed in experimental animals,<sup>190</sup> unfortunately, this process has not been adequately studied in humans. On the other hand, plasma sTM levels are also strongly dependent on renal excretory function.<sup>132,135</sup> It was reported that renal function serves as a determinant of plasma levels of endothelial markers.<sup>191</sup> It was found that there is a significant increase of sTM levels in conservatively treated renal patients without evidence of liver dysfunction. Therefore, interpretation of sTM levels in clinical studies should be performed with close attention to liver and renal function, and testing the markers of liver and renal functions is necessary for the clinical application. All these together illustrate the high demand for fully understanding of the precise structure domain, functional relevance, and activity of sTM and MV-TM in serum and other biofluids, all which will be very essential to comprehend their significance and role in diseases and can be explored as a biomarker for diagnosis and tracking diseases development, therapeutic efficacy and clinical outcome assessment.

**Sources of Funding** X.-L.S. is supported by research grant from the U.S. National Heart, Lung, and Blood Institute of the National Institutes of Health under award no. 1R15HL138544-01.

#### Conflict of Interest

The authors declare no competing financial interests.

#### Acknowledgments

The authors acknowledge the research support from Faculty Research Development Grant and the Research Fund from the Center for Gene Regulation in Health and Disease (GRHD) at the , Cleveland, Ohio, United States.

#### Author Contribution

M.B., T.H.-M., and X.-L.S. prepared the first draft; all authors contributed to the concept, literature search, conclusions, and editing of the final version.

#### References

- 1 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. *Proc Natl Acad Sci U S A* 1981;78(04):2249-2252
- 2 Wen DZ, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE. Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. *Biochemistry* 1987;26(14):4350-4357
- 3 Collins CL, Schaefer R, Cook CD, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. *Am J Pathol* 1992;141(04):827-833
- 4 Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets. *J Biochem* 1988;104(04):628-632
- 5 McCachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. *Blood* 1991;78(12):3128-3132
- 6 Suzuki K, Kusumoto H, Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. *EMBO J* 1987;6(07):1891-1897
- 7 Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. *Am J Physiol Heart Circ Physiol* 2013;304(12):H1585-H1597
- 8 Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. *J Clin Invest* 2005;115(05):1267-1274
- 9 Shi CS, Shi GY, Hsiao HM, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. *Blood* 2008;112(09):3661-3670
- 10 Hsu YY, Shi GY, Wang KC, Ma CY, Cheng TL, Wu HL. Thrombomodulin promotes focal adhesion kinase activation and contributes to angiogenesis by binding to fibronectin. *Oncotarget* 2016;7(42):68122-68139
- 11 Foley JH, Kim PY, Hendriks D, Morser J, Gils A, Mutch NJS. Subcommittee on Fibrinolysis. Evaluation of and recommendation for the nomenclature of the CPB2 gene product (also known as TAFI and proCPU): communication from the SSC of the ISTH. *J Thromb Haemost* 2015;13(12):2277-2278
- 12 Kurosawa S, Stearns DJ, Jackson KW, Esmon CTA. A 10-kDa cyanogen bromide fragment from the epidermal growth factor homology domain of rabbit thrombomodulin contains the primary thrombin binding site. *J Biol Chem* 1988;263(13):5993-5996
- 13 White CE, Hunter MJ, Meininger DP, White LR, Komives EA. Large-scale expression, purification and characterization of small fragments of thrombomodulin: the roles of the sixth domain and of methionine 388. *Protein Eng* 1995;8(11):1177-1187
- 14 Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. *Thromb Haemost* 1997;78(01):386-391
- 15 Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. *J Biol Chem* 1992;267(09):6164-6170
- 16 Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. *J Biol Chem* 2000;275(30):22942-22947
- 17 Hamada H, Ishii H, Sakyo K, Horie S, Nishiki K, Kazama M. The epidermal growth factor-like domain of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. *Blood* 1995;86(01):225-233
- 18 Tohda G, Oida K, Okada Y, et al. Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 1998;18(12):1861-1869
- 19 Gerlitz B, Hassell T, Vlahos CJ, Parkinson JF, Bang NU, Grinnell BW. Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine474. *Biochem J* 1993;295(pt. 1):131-140
- 20 Edano T, Kumai N, Mizoguchi T, Ohkuchi M. The glycosylation sites and structural characteristics of oligosaccharides on recombinant human thrombomodulin. *Int J Biochem Cell Biol* 1998;30(01):77-88
- 21 Lin JH, McLean K, Morser J, et al. Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. *J Biol Chem* 1994;269(40):25021-25030

- 22 Koyama T, Parkinson JF, Sié P, Bang NU, Müller-Berghaus G, Preissner KT. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. *Eur J Biochem* 1991;198(03):563–570
- 23 Elisen MG, von dem Borne PA, Bouma BN, Meijers JC. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. *Blood* 1998;91(05):1542–154
- 24 Weiler H, Isermann BH. Thrombomodulin. *J Thromb Haemost* 2003;1(07):1515–1524
- 25 Teasdale MS, Bird CH, Bird P. Internalization of the anticoagulant thrombomodulin is constitutive and does not require a signal in the cytoplasmic domain. *Immunol Cell Biol* 1994;72(06):480–488
- 26 Conway EM, Nowakowski B, Steiner-Mosonyi M. Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis. *J Cell Physiol* 1994;158(02):285–298
- 27 Boehme MWJ, Galle P, Stremmel W. Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals. *Immunology* 2002;107(03):340–349
- 28 Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. *J Clin Invest* 1985;76(06):2178–2181
- 29 Conway EM, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. *Blood* 1993;81(03):726–733
- 30 Uehara S, Gotoh K, Handa H. Separation and characterization of the molecular species of thrombomodulin in the plasma of diabetic patients. *Thromb Res* 2001;104(05):325–332
- 31 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. *Blood* 1990;76(10):2024–2029
- 32 Califano F, Giovannello T, Pantone P, et al. Clinical importance of thrombomodulin serum levels. *Eur Rev Med Pharmacol Sci* 2000;4(03):59–66
- 33 Wu KK. Soluble thrombomodulin and coronary heart disease. *Curr Opin Lipidol* 2003;14(04):373–375
- 34 Matsumoto H, Yamakawa K, Ogura H, Koh T, Matsumoto N, Shimazu T. Enhanced expression of cell-specific surface antigens on endothelial microparticles in sepsis-induced disseminated intravascular coagulation. *Shock* 2015;43(05):443–449
- 35 Öhlin AK, Larsson K, Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. *J Thromb Haemost* 2005;3(05):976–982
- 36 Haznedaroğlu IC, Erdem Y, Yalcin AU, et al. Circulating thrombomodulin as a molecular marker of endothelium damage in renal transplant recipients. *Nephron* 1996;73(03):486–487
- 37 Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. *Virulence* 2013;4(06):507–516
- 38 Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential. *Crit Care* 2019;23(01):280
- 39 Kurosawa S, Stearns-Kurosawa DJ, Kinasewitz GT. Soluble thrombomodulin: a sign of bad times. *Crit Care Med* 2008;36(03):985–987
- 40 Iba T, Yagi Y, Kidokoro A, Fukunaga M, Fukunaga T. Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. *Surg Today* 1995;25(07):585–590
- 41 Lin SM, Wang YM, Lin HC, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. *Crit Care Med* 2008;36(03):683–689
- 42 Ueno H, Hirasawa H, Oda S, Shiga H, Nakanishi K, Matsuda K. Coagulation/fibrinolysis abnormality and vascular endothelial damage in the pathogenesis of thrombocytopenic multiple organ failure. *Crit Care Med* 2002;30(10):2242–2248
- 43 Dharmasaroja P, Dharmasaroja PA, Sobhon P. Increased plasma soluble thrombomodulin levels in cardioembolic stroke. *Clin Appl Thromb Hemost* 2012;18(03):289–293
- 44 Jourdy Y, Enjolras N, Le Quellec S, et al. Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin? *PLoS One* 2017;12(11):e0188213
- 45 Langdown J, Luddington RJ, Huntington JA, Baglin TP. A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop). *Blood* 2014;124(12):1951–1956
- 46 Dargaud Y, Scoazec JY, Wieters SJH, et al. Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation. *Blood* 2015;125(09):1497–1501
- 47 Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. *Blood* 2018;132(02):148–158
- 48 Boffa MC, Karmochkine M. Thrombomodulin: an overview and potential implications in vascular disorders. *Lupus* 1998;7(Suppl 2):S120–S125
- 49 MacGregor IR, Perrie AM, Donnelly SC, Haslett C. Modulation of human endothelial thrombomodulin by neutrophils and their release products. *Am J Respir Crit Care Med* 1997;155(01):47–52
- 50 Lohi O, Urban S, Freeman M. Diverse substrate recognition mechanisms for rhomboids; thrombomodulin is cleaved by Mammalian rhomboids. *Curr Biol* 2004;14(03):236–241
- 51 van den Berg CW, Gonçalves-de-Andrade RM, Magnoli FC, Tambourgi DV. Loxosceles spider venom induces the release of thrombomodulin and endothelial protein C receptor: implications for the pathogenesis of intravascular coagulation as observed in loxoscelism. *J Thromb Haemost* 2007;5(05):989–995
- 52 Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. *Am J Respir Cell Mol Biol* 2007;36(04):497–503
- 53 Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2003;285(03):L514–L521
- 54 Boehme MWJ, Deng Y, Raeth U, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF- $\alpha$  and neutrophils: in vivo and in vitro studies. *Immunology* 1996;87(01):134–140
- 55 Wu HL, Lin CI, Huang YL, et al. Lysophosphatidic acid stimulates thrombomodulin lectin-like domain shedding in human endothelial cells. *Biochem Biophys Res Commun* 2008;367(01):162–168
- 56 Cheng TL, Wu YT, Lin HY, et al. Functions of rhomboid family protease RHBDL2 and thrombomodulin in wound healing. *J Invest Dermatol* 2011;131(12):2486–2494
- 57 Abe H, Okajima K, Okabe H, Takatsuki K, Binder BR. Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. *J Lab Clin Med* 1994;123(06):874–881
- 58 Menschikowski M, Hagelgans A, Eisenhofer G, Tiesel O, Siegert G. Reducing agents induce thrombomodulin shedding in human endothelial cells. *Thromb Res* 2010;126(02):e88–e93
- 59 Glaser CB, Morser J, Clarke JH, et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. *J Clin Invest* 1992;90(06):2565–2573
- 60 Ando J, Yamamoto K. Effects of shear stress and stretch on endothelial function. *Antioxid Redox Signal* 2011;15(05):1389–1403
- 61 Ishibazawa A, Nagaoka T, Takahashi T, et al. Effects of shear stress on the gene expressions of endothelial nitric oxide synthase, endothelin-1, and thrombomodulin in human retinal microvascular endothelial cells. *Invest Ophthalmol Vis Sci* 2011;52(11):8496–8504

- 62 Martin FA, McLoughlin A, Rochfort KD, Davenport C, Murphy RP, Cummins PM. Regulation of thrombomodulin expression and release in human aortic endothelial cells by cyclic strain. *PLoS One* 2014;9(09):e108254
- 63 Barteneva NS, Fasler-Kan E, Bernimoulin M, et al. Circulating microparticles: square the circle. *BMC Cell Biol* 2013;14:23
- 64 Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. *J Intensive Care* 2015;3(01):2
- 65 VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. *Cardiovasc Res* 2003;59(02):277–287
- 66 Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. *Curr Opin Hematol* 2004;11(03):156–164
- 67 Satta N, Freyssinet JM, Toti F. The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccharide. *Br J Haematol* 1997;96(03):534–542
- 68 Bouchama A, Kunzelmann C, Dehbi M, et al. Recombinant activated protein C attenuates endothelial injury and inhibits procoagulant microparticles release in baboon heatstroke. *Arterioscler Thromb Vasc Biol* 2008;28(07):1318–1325
- 69 Ogura H, Tanaka H, Koh T, et al. Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. *J Trauma* 2004;56(04):823–830, discussion 830–831
- 70 Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. *Thromb Res* 2010;126(03):238–242
- 71 Andriantsitohaina R, Gaceb A, Vergori L, Martínez MC. Microparticles as regulators of cardiovascular inflammation. *Trends Cardiovasc Med* 2012;22(04):88–92
- 72 Boscolo A, Campello E, Bertini D, et al. Levels of circulating microparticles in septic shock and sepsis-related complications: a case-control study. *Minerva Anestesiol* 2019;85(06):625–634
- 73 Campello E, Zanetto A, Radu CM, et al. Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. *Dig Liver Dis* 2021;53(07):879–888
- 74 Campello E, Zanetto A, Spiezia L, et al. Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. *Thromb Res* 2016;143:118–121
- 75 Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. *N Engl J Med* 2009;361(04):345–357
- 76 Westbury SK, Whyte CS, Stephens J, et al; NIH BioResource. A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency. *J Thromb Haemost* 2020;18(09):2209–2214
- 77 Rehill AM, Preston RJS. A new thrombomodulin-related coagulopathy. *J Thromb Haemost* 2020;18(09):2123–2125
- 78 Frigerio S, Ariano C, Bernardi G, et al. Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients. *J Neuroimmunol* 1998;87(1-2):88–93
- 79 Balkuv E, Varoglu AO, Isik N, et al. The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis. *Mult Scler Relat Disord* 2016;8:131–135
- 80 Jansson JH, Boman K, Brännström M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. *Circulation* 1997;96(09):2938–2943
- 81 Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Mochizuki H. Species specificity of the anticoagulant activity of human urinary soluble thrombomodulin. *Thromb Res* 1998;89(04):187–197
- 82 Seigneur M, Dufourcq P, Conri C, et al. Plasma thrombomodulin: new approach of endothelium damage. *Int Angiol* 1993;12(04):355–359
- 83 Menashi S, Arousseau MH, Gozin D, et al. High levels of circulating thrombomodulin in human fetuses and children. *Thromb Haemost* 1999;81(06):906–909
- 84 Schneider P, Van Dreden P, Rousseau A, et al. Decreased activity of soluble thrombomodulin and plasma procoagulant phospholipids in childhood bone marrow transplantation with severe complications. *Thromb Res* 2011;128(03):261–267
- 85 Rousseau A, Favier R, Van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia? *Eur J Obstet Gynecol Reprod Biol* 2009;146(01):46–49
- 86 Brunelli T, Prisco D, Fedi S, et al. High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. *J Vasc Surg* 2000;32(03):531–536
- 87 Donnelly SC, MacGregor I, Zamani A, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. *Am J Respir Crit Care Med* 1995;151(05):1428–1433
- 88 Maknitikul S, Luplertlop N, Grau GER, Ampawong S. Dysregulation of pulmonary endothelial protein C receptor and thrombomodulin in severe falciparum malaria-associated ARDS relevant to hemozoin. *PLoS One* 2017;12(07):e0181674
- 89 Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. *Blood* 1986;67(02):362–365
- 90 Bajaj MS, Kuppaswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. *Thromb Haemost* 1999;82(03):1047–1052
- 91 McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. *Crit Care* 2008;12(02):R41
- 92 Faix JD. Biomarkers of sepsis. *Crit Rev Clin Lab Sci* 2013;50(01):23–36
- 93 Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. *Lancet Haematol* 2020;7(08):e575–e582
- 94 Jin X, Duan Y, Bao T, et al. The values of coagulation function in COVID-19 patients. *PLoS One* 2020;15(10):e0241329
- 95 el-Gamal YM, Heshmat NM, el-Kerdany TH, Fawzy AF. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis. *Pediatr Allergy Immunol* 2004;15(03):270–277
- 96 Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—a review. *Crit Care Med* 2006;34(03):871–877
- 97 Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;336(04):243–250
- 98 Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;58(05):377–382
- 99 Yin Q, Liu B, Chen Y, Zhao Y, Li C. Soluble thrombomodulin to evaluate the severity and outcome of community-acquired pneumonia. *Inflammation* 2014;37(04):1271–1279
- 100 Liu Z-H, Wei R, Wu Y-P, et al. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. *Biomed Environ Sci* 2005;18(04):260–264
- 101 Wada H, Ohiwa M, Kaneko T, et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. *Am J Hematol* 1992;39(01):20–24
- 102 Levi M, van der Poll T. Inflammation and coagulation. *Crit Care Med* 2010;38(2, suppl):S26–S34
- 103 Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. *Immunity* 2014;40(04):463–475



- 104 Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. *N Engl J Med* 2001;345(06):408–416
- 105 Mihajlovic DM, Lendak DF, Draskovic BG, et al. Thrombomodulin is a strong predictor of multiorgan dysfunction syndrome in patients with sepsis. *Clin Appl Thromb Hemost* 2015;21(05):469–474
- 106 Lin JJ, Hsiao HJ, Chan OW, Wang Y, Hsia SH, Chiu CH. Increased serum thrombomodulin level is associated with disease severity and mortality in pediatric sepsis. *PLoS One* 2017;12(08):e0182324
- 107 Siasos G, Mourouzis K, Oikonomou E, et al. The role of endothelial dysfunction in aortic aneurysms. *Curr Pharm Des* 2015;21(28):4016–4034
- 108 Budzyń M, Gryszczyńska B, Majewski W, et al. The association of serum thrombomodulin with endothelial injuring factors in abdominal aortic aneurysm. *BioMed Res Int* 2017;2017:2791082
- 109 Öhlin AK, Morser J, Öhlin H. Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. *Thromb Res* 1996;82(04):313–322
- 110 Van Dreden P, Rousseau A, Savoure A, Lenormand B, Fontaine S, Vasse M. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. *Blood Coagul Fibrinolysis* 2009;20(08):635–641
- 111 Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. *Lancet* 1999;353(9166):1729–1734
- 112 Elsalakawy W, Farweez BT, Sallam MH, Hamza M. High levels of soluble thrombomodulin may be a marker of arterial disease and peripheral ischemia in Egyptian patients with diabetes mellitus. *Egypt J Haematol* 2014;39:52–57
- 113 John S, Drobnik W, Lackner K, Schmieder RE. Soluble thrombomodulin and endothelial dysfunction in early atherosclerosis. *Lancet* 1999;354(9190):1647
- 114 Karakas M, Baumert J, Herder C, et al. Soluble thrombomodulin in coronary heart disease: lack of an association in the MONICA/KORA case-cohort study. *J Thromb Haemost* 2011;9(05):1078–1080
- 115 Wada H, Minamikawa K, Wakita Y, et al. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. *Am J Hematol* 1993;44(02):85–88
- 116 Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. *Am J Hematol* 1998;58(03):189–194
- 117 Gando S, Nakanishi Y, Kameue T, Nanzaki S. Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: role of neutrophil elastase. *J Trauma* 1995;39(04):660–664
- 118 Wada H, Kaneko T, Ohiwa M, et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. *Am J Hematol* 1993;44(02):101–105
- 119 Mori Y, Wada H, Okugawa Y, et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Clin Appl Thromb Hemost* 2001;7(01):5–9
- 120 Nevard CHF, Blann AD, Jurd KM, Haycock GB, Hunt BJ. Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome. *Pediatr Nephrol* 1999;13(06):487–492
- 121 McLaren M, Elhadd TA, Greene SA, Belch JJJF. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. *Clin Appl Thromb Hemost* 1999;5(01):21–24
- 122 Gabat S, Keller C, Kempe HP, et al. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. *Vasa* 1996;25(03):233–241
- 123 Aslan B, Eren N, Cifci S, Müldür F, Yücel N. Evaluation of plasma protein C antigen, protein C activity and thrombomodulin levels in type 2 diabetic patients. *Turk J Med Sci* 2005;35:305–310
- 124 Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. *Diabetes* 1985;34(07):621–627
- 125 von Scholten BJ, Reinhard H, Hansen TW, et al. Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. *J Diabetes Complications* 2016;30(02):248–255
- 126 Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Nakanishi N. Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. *Chest* 2003;124(04):1305–1311
- 127 Shimano H, Takahashi K, Kawakami M, et al. Elevated serum and urinary thrombomodulin levels in patients with non-insulin-dependent diabetes mellitus. *Clin Chim Acta* 1994;225(02):89–96
- 128 Stratton RJ, Pompon L, Coghlan JG, Pearson JD, Black CM. Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. *Ann Rheum Dis* 2000;59(02):132–134
- 129 Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R. Circulating thrombomodulin levels are related to latent progression of atherosclerosis in hypertensive patients. *Hypertens Res* 2003;26(06):479–483
- 130 Papadopoulos DP, Thomopoulos C, Mourouzis I, et al. Masked hypertension unfavourably affects haemostasis parameters. *Blood Press* 2011;20(04):218–221
- 131 Hergesell O, Andrassy K, Geberth S, Nawroth P, Gabath S. Plasma thrombomodulin levels are dependent on renal function. *Thromb Res* 1993;72(05):455–458
- 132 Rustom R, Leggat H, Tomura HR, Hay CR, Bone JM. Plasma thrombomodulin in renal disease: effects of renal function and proteinuria. *Clin Nephrol* 1998;50(06):337–341
- 133 Bao YS, Jia XB, Wang D, Liu RC, Zou CB, Na SP. Characterization of soluble thrombomodulin levels in patients with stage 3–5 chronic kidney disease. *Biomarkers* 2014;19(04):275–280
- 134 Katayama S, Nunomiya S, Koyama K, et al. Markers of acute kidney injury in patients with sepsis: the role of soluble thrombomodulin [in Japanese]. *Crit Care* 2017;21(01):229
- 135 Mezzano D, Tagle R, Pais E, et al. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. *Thromb Res* 1997;88(06):465–472
- 136 Conway EM. Thrombomodulin and its role in inflammation. *Semin Immunopathol* 2012;34(01):107–125
- 137 Ikeguchi H, Maruyama S, Morita Y, et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis. *Kidney Int* 2002;61(02):490–501
- 138 Akiyama K, Nakamura K, Makino I. Evaluation of plasma thrombomodulin (TM) levels in patients with liver disease [in Japanese]. *Nippon Shokakibyō Gakkai Zasshi* 1992;89(10):2559–2567
- 139 Zeniya M, Fukata H, Toda G. Thrombomodulin expression of sinusoidal endothelial cells in chronic viral hepatitis. *J Gastroenterol Hepatol* 1995;10(Suppl 1):S77–S80
- 140 Borawski J, Naumnik B, Pawlak K, Myśliwiec M. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. *Nephrol Dial Transplant* 2001;16(04):787–792

- 141 Takatori M, Iwabuchi S, Ro S, et al. Increased serum levels and sinusoidal expression of thrombomodulin in acute liver damage. *Thromb Res* 1999;93(03):113–120
- 142 El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. *Circulation* 2004;110(04):399–404
- 143 Kahlenberg JM, Kaplan MJ. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. *Arthritis Res Ther* 2011;13(01):203
- 144 Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. *Blood* 2004;103(10):3677–3683
- 145 Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. *Arthritis Rheum* 1996;39(01):9–22
- 146 Boehme MW, Nawroth PP, Kling E, et al. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. *Arthritis Rheum* 1994;37(04):572–577
- 147 Witte T, Hartung K, Sachse C, et al. Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. *Rheumatol Int* 2000;19(03):107–111
- 148 Kiraz S, Ertenli I, Benekli M, et al. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. *Lupus* 1999;8(09):737–741
- 149 Karmochkine M, Boffa MC, Piette JC, et al. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies. *Blood* 1992;79(03):837–838
- 150 Festoff BW, Li C, Woodhams B, Lynch S. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication. *J Neurol Sci* 2012;323(1,2):61–65
- 151 Horák P, Ščudla V, Hermanová Z, et al. Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. *Clin Rheumatol* 2001;20(05):337–344
- 152 Akbarian M, Gharibdoost F, Hadjaliloo M, et al. Assessment of serum thrombomodulin in patients with systemic lupus erythematosus in rheumatology research center. *Acta Med Iran* 2009;47:97–102
- 153 Edelbauer M, Kshirsagar S, Riedl M, et al. Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis. *Pediatr Nephrol* 2012;27(05):793–800
- 154 Urban M, Wojtkielewicz K, Głowińska B, Peczyńska J. [Soluble thrombomodulin—a molecular marker of endothelial cell injury in children and adolescents with obesity]. *Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw* 2005;11(02):73–77
- 155 Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. *J Cell Biol* 1985;101(02):363–371
- 156 Fazel A, Vincenot A, Malassiné A, et al. Increase in expression and activity of thrombomodulin in term human syncytiotrophoblast microvilli. *Placenta* 1998;19(04):261–268
- 157 Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. *Blood* 1990;75(02):329–336
- 158 Minakami H, Takahashi T, Izumi A, Tamada T. Increased levels of plasma thrombomodulin in preeclampsia. *Gynecol Obstet Invest* 1993;36(04):208–210
- 159 Bontis J, Vavilis D, Agorastos T, Zournatzi V, Konstantinidis T, Tagou K. Maternal plasma level of thrombomodulin is increased in mild preeclampsia. *Eur J Obstet Gynecol Reprod Biol* 1995;60(02):139–141
- 160 Dusse LM, Carvalho MG, Getliffe K, Voegeli D, Cooper AJ, Lwaleed BA. Increased circulating thrombomodulin levels in pre-eclampsia. *Clin Chim Acta* 2008;387(1-2):168–171
- 161 Prochazka M, Procházková J, Lubušký M, et al. Markers of endothelial activation in preeclampsia. *Clin Lab* 2015;61(1-2):39–46
- 162 de Moerloose P, Mermillod N, Amiral J, Reber G. Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1. *Thromb Haemost* 1998;79(03):554–556
- 163 Boffa MC, Vasecchi L, Fausto A, et al. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. *Thromb Haemost* 1998;79(06):1092–1095
- 164 Bosco C, Parra M, Barja P, et al. Increased immunohistochemical expression of thrombomodulin at placental perivascular myofibroblast in severe preeclampsia (PE). *Histol Histopathol* 2005;20(04):1045–1055
- 165 Johansson L, Jansson J-H, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Prospective study on soluble thrombomodulin and von Willebrand factor and the risk of ischemic and hemorrhagic stroke. *Thromb Haemost* 2002;87(02):211–217
- 166 Hassan A, Hunt BJ, O'Sullivan M, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. *Brain* 2003;126(Pt 2):424–432
- 167 Nomura E, Kohriyama T, Kozuka K, Kajikawa H, Nakamura S, Matsumoto M. Significance of serum soluble thrombomodulin level in acute cerebral infarction. *Eur J Neurol* 2004;11(05):329–334
- 168 Giordano S, Spiezia L, Campello E, Simioni P. The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. *Intern Emerg Med* 2017;12(07):981–991
- 169 Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? *Ann Surg* 2007;245(05):812–818
- 170 Hanly AM, Winter DC. The role of thrombomodulin in malignancy. *Semin Thromb Hemost* 2007;33(07):673–679
- 171 Iqbal S. Role of thrombomodulin in cancer biology. *Breast* 2000;9(05):264–266
- 172 Asanuma K, Nakamura T, Asanuma Y, et al. Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas. *Cancer Biomark* 2019;26(02):163–170
- 173 Arazi HC, Doiny DG, Torcivia RS, et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. *Interact Cardiovasc Thorac Surg* 2010;10(06):863–867
- 174 Cohen Arazi H. Soluble Thrombomodulin Levels are Related to Inflammation after Coronary Bypass Surgery. *J Clin Exp Cardiol* 2011;02:2–4
- 175 Chao TH, Li YH, Tsai WC, Chen JH, Liu PY, Tsai LM. Elevation of the soluble thrombomodulin levels is associated with inflammation after percutaneous coronary interventions. *Clin Cardiol* 2004;27(07):407–410
- 176 Kim H, Hawthorne WJ, Kang HJ, et al. Human thrombomodulin regulates complement activation as well as the coagulation cascade in xeno-immune response. *Xenotransplantation* 2015;22(04):260–272
- 177 Sido B, Datsis K, Mehrabi A, et al. Soluble thrombomodulin—a marker of reperfusion injury after orthotopic liver transplantation. *Transplantation* 1995;60(05):462–466
- 178 Himmelreich G, Riewald M, Rosch R, et al. Thrombomodulin: a marker for endothelial damage during orthotopic liver transplantation. *Am J Hematol* 1994;47(01):1–5
- 179 Eng HL, Chen YS, Jawan B, et al. Soluble thrombomodulin antigen as a marker for endothelial damage during liver transplantation. *Transplant Proc* 2000;32(07):2273–2275
- 180 Tomura S, Nakamura Y, Deguchi F, et al. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. *Thromb Res* 1990;58(04):413–419

- 181 Nakamura Y, Tomura S, Tachibana K, Chida Y, Marumo F. Enhanced fibrinolytic activity during the course of hemodialysis. *Clin Nephrol* 1992;38(02):90–96
- 182 Van Gennip ACE, Broers NJH, Ter Meulen KJ, et al. Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy. *PLoS One* 2019;14:1–20
- 183 Sioulis A, Malindretos P, Makedou A, Makris P, Grekas D. Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients. *Hippokratia* 2009;13(04):237–241
- 184 Suehiro T, Boros P, Sheiner P, et al. Effluent levels of thrombomodulin predict early graft function in clinical liver transplantation. *Liver* 1997;17(05):224–229
- 185 Jackson DE, Tetaz TJ, Salem HH, Mitchell CA. Purification and characterization of two forms of soluble thrombomodulin from human urine. *Eur J Biochem* 1994;221(03):1079–1087
- 186 Ishii H, Nakano M, Tsubouchi J, et al. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. *Thromb Haemost* 1990;63(02):157–162
- 187 Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. *Thromb Haemost* 1998;79(02):371–377
- 188 Freyssinet JM. Cellular microparticles: what are they bad or good for? *J Thromb Haemost* 2003;1(07):1655–1662
- 189 Borawski J, Naumnik B, Myśliwiec M. Increased soluble thrombomodulin does not always indicate endothelial injury. *Clin Appl Thromb Hemost* 2002;8(01):87–89
- 190 Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. *Blood* 1988;71(03):728–733
- 191 Naumnik B, Borawski J, Pawlak K, Myśliwiec M. Renal function, proteinuria and ACE-inhibitor therapy as determinants of plasma levels of endothelial markers. *Nephrol Dial Transplant* 2002;17(03):526–528
- 192 Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. *Eur J Clin Invest* 1997;27(11):916–921
- 193 Béland S, Vallin P, Désy O, Lévesque E, De Serres SA. Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. *J Thromb Haemost* 2017;15(05):1020–1031
- 194 Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin-dependent diabetes mellitus. *Diabetes Res Clin Pract* 1996;33(02):99–104
- 195 Folsom AR, Yao L, Alonso A, et al. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2015;132(07):578–585
- 196 Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. *Am J Respir Crit Care Med* 1997;155(04):1187–1205
- 197 Agrawal A, Zhuo H, Brady S, et al. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. *Am J Physiol Lung Cell Mol Physiol* 2012;303(08):L634–L639
- 198 Kampoli AM, Tousoulis D, Antoniadis C, Siasos G, Stefanadis C. Biomarkers of premature atherosclerosis. *Trends Mol Med* 2009;15(07):323–332
- 199 Seligman R, Ramos-Lima LF, Oliveira VdoA, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in community-acquired pneumonia: a state-of-the-art review. *Clinics (São Paulo)* 2012;67(11):1321–1325
- 200 Kim SJ, Moon GJ, Bang OY. Biomarkers for stroke. *J Stroke* 2013;15(01):27–37
- 201 Subirana I, Fitó M, Diaz O, et al. Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism. *Sci Rep* 2018;8(01):3191
- 202 Lyons TJ, Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. *Transl Res* 2012;159(04):303–312
- 203 Shimizu M, Kuroda M, Inoue N, et al. Extensive serum biomarker analysis in patients with enterohemorrhagic *Escherichia coli* O111-induced hemolytic-uremic syndrome. *Cytokine* 2014;66(01):1–6
- 204 Shere A, Eletta O, Goyal H. Circulating blood biomarkers in essential hypertension: a literature review. *J Lab Precis Med* 2017;2:99–99
- 205 Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: the challenging quest. *Rheumatology (Oxford)* 2017;56(suppl\_1):i32–i45
- 206 Ziemssen T, Akgün K, Brück W. Molecular biomarkers in multiple sclerosis [in Polish]. *J Neuroinflammation* 2019;16(01):272
- 207 Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. *Trends Cardiovasc Med* 2008;18(05):186–194
- 208 Che XY, Hao W, Wang Y, et al. Nucleocapsid protein as early diagnostic marker for SARS. *Emerg Infect Dis* 2004;10(11):1947–1949
- 209 Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. *Blood* 2017;130(04):466–471
- 210 Brazelton J, Oster RA, McCleskey B, Fuller J, Adamski J, Marques MB. Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura. *J Clin Apher* 2017;32(05):311–318
- 211 Vielhaber H, Kehl HG, Kececioglu D, Nowak-Göttl U. Plasma thrombomodulin concentrations in infants and children undergoing cardiac catheterization. *Haematologica* 1996;81(05):457–459
- 212 Mota APL, Martins SR, Alves LV, et al. Thrombomodulin and interleukin 6 as potential biomarkers of endothelial dysfunction and inflammation after renal transplant. *J Bras Patol Med Lab* 2018;54(06):379–386